SIXTH WAVE ANNOUNCES ADDITION OF PATRICIA STEADMAN, BSEE, TO THE BOARD OF DIRECTORS

Halifax, Nova Scotia – (August 18, 2022) – Sixth Wave Innovations Inc. (CSE:SIXW) (OTCQB:SIXWF) (FSE:AHUH) (“Sixth Wave” or the “Company“) is pleased to announce that Ms. Patricia Steadman will be joining the Company’s Board of Directors effective immediately. Patricia has been a valuable corporate advisor to the Sixth Wave executive team and is a welcome addition to the Board. This move comes as the Company continues to narrow the corporate focus on the monetization of our established technologies.

Ms. Steadman is a highly accomplished CEO across multiple technology companies and will continue to support the Sixth Wave executive team towards the immediate goal of developing near term revenue. Ms. Steadman’s corporate success will continue to create exciting business applications and opportunities for Sixth Wave. Ms. Steadman holds a Computer Engineering degree from Lehigh University and attended Columbia University for her Masters of Computer Science degree prior to becoming an early pioneer in the Internet messaging and domain fields. Equally, Ms. Steadman brings extensive experience in capital markets, grants, information technology and systems, as well as connectivity to mining and pathogen detection. Ms. Steadman has decades experience as a serial entrepreneur bringing largescale, innovative, and transformative platform technologies to new markets. Ms. Steadman has already been contributing significantly to the Company’s efforts bringing green ESG solutions to gold and battery metal opportunities in the US and Canada.

“I have enjoyed working closely with Ms. Steadman for the past year in various business development initiatives.” said Dr. Jon Gluckman, President & CEO of Sixth Wave. “Ms. Steadman’s diverse experience in industry, government contracting, capital markets, and licensing will be instrumental in supporting our metals and mining focus on revenue generation while extending our ability to monetize the medical and diagnostic achievements we have already made.”

“I am excited to be asked to join the Board and bring additional skill sets to help the Company achieve its goals. Despite difficult times, Sixth Wave has made great strides in last year with successful mining projects, licensing of its Affinity technology, and demonstrating the superiority of its viral/bacterial pathogen detection polymers. I believe that this positions the Company for a solid growth and I look forward to assisting in those efforts” said Ms. Steadman.

The Honorable Grant Mitchell will retire his Board of Director position to Ms. Steadman but will remain as an Advisory Board member where he will continue to champion Sixth Wave’s success in introducing ESG compliant technology to North American industry.
As noted by Senator Mitchell, “It has been an honour for the past three years to have been part of Sixth Wave’s work in applying its MIPs technology to several significant medical and industrial processes and to see the progress that has been achieved. I have greatly enjoyed working with CEO Jon Gluckman, board members and staff. I have been inspired by their leadership, talent and dedication. I am also very happy that I will be able to continue my association with the company by returning to the Advisory Board”.

The Company further reports that it has granted a total of 150,000 options to an independent director of the Company. The options are exercisable at $0.10 per share and will expire on August 19, 2027. One third of the options will vest after six months, with an additional third vesting every six months thereafter until fully vested.

About Sixth Wave
Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its Affinity™ cannabinoid purification system, AMIPS™ virus/bacteria detection, as well as IXOS^®, a line of extraction polymers for the gold mining industry.
Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.
For more information about Sixth Wave, please visit: www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS
“Jon Gluckman”
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes
This press release includes certain statements that may be deemed “forward-looking statements” including possible statements regarding the planned use of proceeds and performance of the IXOS^®, Affinity™, and AMIPs™ technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the IXOS^®, Affinity™, or AMIPs™ technologies are subject to the risk that they may not prove to be successful, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for certain applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if patents are not granted. The Company has not yet applied for regulatory approval for the use of this product from any regulatory agency.